A Study of V118E in Healthy Participants (V118E-003)

Researchers are looking for new vaccines to prevent illnesses caused by a type of bacteria called Streptococcus pneumoniae. There are many different types of Streptococcus pneumoniae bacteria, called serotypes. Vaccines contain small parts of certain serotypes. These parts will not cause an infection but help the body create antibodies (proteins) to fight the bacteria. PREVNAR 20™ is a vaccine given to help to prevent disease from Streptococcus pneumoniae bacteria. Researchers designed a new vaccine, V118E, to help prevent disease from Streptococcus pneumoniae bacteria. The goal of this study is to learn how safe V118 formulation E is in Healthy Adults and how well people tolerate it.

NCT Number	NCT07168915
Lead Sponsor	Merck Sharp & Dohme LLC
Conditions	Healthy
Enrollment	126 participants
Start Date	2025-10-08
Primary Completion	2027-07-06 (estimated)
Study Completion	2027-07-06 (estimated)
Updated on ClinicalTrials.gov	2026-07-15